Current agents in the market include that of tisagenlecleucel or axicabtagene ciloleucel which are specifically targeted against CD19, but these options have only been evaluated in the setting of B-cell lymphomas (216); CAR-T targeting CD30 has also been trialed in the subset of ALCL in an early phase I study (217). This evidence concerns the gene TNFRSF8 and B-cell non-Hodgkin lymphoma.